Mariani M, Prosperi E, Colombo A, Supino R
Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Anticancer Res. 1989 Jan-Feb;9(1):29-32.
We present data on the cellular drug pharmacokinetic alterations correlated with the circumvention of doxorubicin resistance by verapamil in a B16 melanoma cell line. An increased drug uptake, a decreased drug efflux and a different intracellular drug distribution appear to be responsible for the enhancement of doxorubicin cytotoxicity induced by treatment with verapamil in drug-resistant cells. However, doxorubicin pharmacokinetics and cytotoxicity were not affected by verapamil in doxorubicin-sensitive melanoma cells.
我们展示了在B16黑色素瘤细胞系中，与维拉帕米克服阿霉素耐药性相关的细胞药物药代动力学改变的数据。药物摄取增加、药物外排减少以及细胞内药物分布不同，似乎是维拉帕米处理耐药细胞后增强阿霉素细胞毒性的原因。然而，在阿霉素敏感的黑色素瘤细胞中，维拉帕米并未影响阿霉素的药代动力学和细胞毒性。
